webinar register page

Beyond X-ing the X-Waiver

At the end of 2022, President Biden signed into law the removal of the X-Waiver requirement to prescribe buprenorphine to treat opioid use disorder (OUD). This is seen as a first step towards increasing access to OUD treatment, however, X-ing the X-Waiver, on its own, may not drive the increases in buprenorphine prescribing where its needed most. Many primary care providers have not received training in OUD treatment and how to engage patients in long-term treatment or connect them to supports needed for recovery. New providers in all healthcare settings will need training, mentorship, and coaching, and continued efforts are needed to reduce stigma, manage privacy, address disparities, and build a community of practice in which it is expected to care for OUD patients.

Many FORE grantees are showing how these challenges can be met. One grantee is leading a national campaign to encourage other emergency department clinicians to treat OUD patients by leveraging social media and behavioral science to encourage clinicians to get the training they need to start to prescribe buprenorphine. Another is offering OUD treatment education to resident physicians, medical students, and physician assistant students. These are just a few examples of next steps needed to truly expand access to OUD treatment for all.

Please join us on Thursday, March 9th at 3pm EST as we welcome…

H. Westley Clark, MD, JD, MPH, Board Member
Board of Directors
Foundation for Opioid Response Efforts (FORE)

Alister Martin, MD, MPP, Assistant Professor
Grantee: Massachusetts General Hospital
Project: ‘Get Waivered’ National

Lara Weinstein, MD, MPH, DrPH, Associate Professor
Grantee: Thomas Jefferson University
Project: Lowering Barriers, Saving Lives, Reclaiming Health: Integrating Medications for Opioid Use Disorder

… as they discuss policy implications and next steps after removal of the X-Waiver and provide some recommendations for the field.

Mar 9, 2023 03:00 PM in Eastern Time (US and Canada)